Pathologists Versus AI
Artificial intelligence (AI) systems for pathology may appear to compete with manual pathology, as they enable the assessment of thousands of cells and application of
CIOReview Names Flagship Company of the Year
CIOReview named Flagship Biosciences “Company of the Year,” as part of the publication’s 2018 20 Most Promising Pharma & Life Sciences Tech Solution Providers industry
POSTER: Using Artificial Intelligence to Predict Response to Immunotherapy
Key Concepts: Pathological interpretations applied to PD-L1 IHC as a response biomarker are becoming more complex, going beyond simple tumor proportion score (TPS) and requiring
POSTER: Pathology AI (Artificial Intelligence)
Deep learning has created a hype about artificial intelligence (AI) and healthcare AI. Flagship Biosciences has been developing a pathology AI system over the last
Intelligent Pharma Partners: Pathology AI Needs a New Business Model
The true barrier to artificial intelligence (AI) in pathology is not the technology; it’s the business model. Flagship Biosciences believes that the true opportunity for
2018 Global AI-based Pathology Solutions in Immuno-oncology Technology Innovation Award
Based on its recent analysis of the global market for artificial intelligence (AI)-based pathology solutions in immuno-oncology (I-O), Frost & Sullivan recognizes Flagship Biosciences, Inc.
